MIRA Pharmaceuticals, Inc.
$1.12
▲
4.72%
2026-04-21 08:09:01
mirapharmaceuticals.com
NCM: MIRA
Explore MIRA Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$47.06 M
Current Price
$1.12
52W High / Low
$2.45 / $0.83
Stock P/E
—
Book Value
$0.25
Dividend Yield
—
ROCE
-100.98%
ROE
-1.66%
Face Value
—
EPS
$-1.31
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
—
Beta
1.94
Debt / Equity
5.51
Current Ratio
15.75
Quick Ratio
15.75
Forward P/E
-2.43
Price / Sales
—
Enterprise Value
$31.42 M
EV / EBITDA
—
EV / Revenue
—
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Nasus Pharma Ltd. | $2.86 | — | $19.29 M | — | -172.62% | 2637.84% | $9.99 / $1.98 | $0.31 |
| 2. | AbbVie Inc. | NOT FOUND | 86.59 | $360.82 B | 3.4% | 22.16% | 62.25% | $244.81 / $168.54 | $-1.85 |
| 3. | Scilex Holding Company | $6.95 | — | $58.97 M | — | 55.67% | 39.83% | $34.27 / $3.6 | $-29.75 |
| 4. | Eli Lilly and Company | $921 | 40.12 | $868.52 B | 0.75% | 38.44% | 1.01% | $1,133.95 / $623.78 | $29.66 |
| 5. | Bristol-Myers Squibb Company | $59.38 | 17.16 | $121.36 B | 4.26% | 20.6% | 40.44% | $62.89 / $42.52 | $9.07 |
| 6. | AstraZeneca PLC | $196.47 | 30 | $305.64 B | 1.58% | 15.97% | 22.84% | $15,730 / $9,651 | $31.38 |
| 7. | Novo Nordisk A/S | $39.12 | 10.82 | $131.02 B | 4.54% | 39.01% | 60.7% | $533.4 / $224.25 | $6.83 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -5.82 M | -1.32 M | -1.55 M | -1.81 M | -2.44 M | — |
| Net Profit | -5.98 M | -1.14 M | -1.54 M | -1.78 M | -2.4 M | — |
| EPS in Rs | -0.14 | -0.03 | -0.04 | -0.04 | -0.06 | -0.14 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -10.49 M | -8.02 M | -8.53 M | -7.05 M |
| Net Profit | -10.44 M | -7.85 M | -11.98 M | -7.06 M |
| EPS in Rs | -0.25 | -0.19 | -0.29 | -0.17 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 11.09 M | 2.92 M | 4.93 M | 0.86 M |
| Total Liabilities | 0.7 M | 0.72 M | 0.56 M | 1.45 M |
| Equity | 10.39 M | 2.2 M | 4.37 M | -0.6 M |
| Current Assets | 11.06 M | 2.89 M | 4.86 M | 0.49 M |
| Current Liabilities | 0.7 M | 0.72 M | 0.56 M | 1.37 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -4.66 M | -5.56 M | -4.53 M | -5.6 M |
| Investing CF | — | — | — | — |
| Financing CF | 8.18 M | 3.79 M | 8.78 M | 3.15 M |
| Free CF | -4.66 M | -5.56 M | -4.53 M | -5.6 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 34.46% | -69.77% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.